Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. - Wikidata - wikimedia - TriplyDB

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

http://www.wikidata.org/entity/Q35096719

about

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.The Association between Elevated Levels of Peripheral Serotonin and Its Metabolite - 5-Hydroxyindoleacetic Acid and Bone Strength and Metabolism in Growing Rats with Mild Experimental Chronic Kidney Disease Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease.Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease Sclerostin is essential for alveolar bone loss in occlusal hypofunction Inhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism.Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.Role and mechanism of action of sclerostin in bone.The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease.The Expanding Life and Functions of Osteogenic Cells: From Simple Bone-Making Cells to Multifunctional Cells and Beyond.Application of anti-Sclerostin therapy in non-osteoporosis disease models.Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy.

P2860

Q26744599-67C693F3-AC86-4D3C-9D38-E2FAC95F40BC Q27334345-76B98403-D9A8-48F7-9097-A860549B9A29 Q30235173-2D0D0783-3AE5-406A-81A3-F37F8824D5D0 Q35661168-2DFB18D6-E0A6-45F6-9BB5-BFFA538BA2CE Q36104700-06C9C74C-327F-4139-97D5-715D0C349A21 Q36155291-4CF183B0-1542-4D50-B5E7-212A29344DB2 Q36497898-B25CF1CD-0265-4920-9D3E-CAF34FDB1D15 Q36666085-9532721F-46DB-4CF3-B161-B6462EF3C7C2 Q36823369-9B161699-F383-47FF-A1A6-EA6AF6132832 Q36824778-B74C4518-D501-4D54-AFAF-6F3734AB29EA Q37418997-B16CEB91-3055-45B8-AD40-5437B2675D7F Q38569480-7009CB9D-C95F-48F1-82CB-0C2C85B869DB Q38807230-587DEE93-1A90-41CF-AA99-08134B4D382B Q38810794-63EC691B-0954-46F0-BC38-CA3790F12B4E Q39101623-2A1DC4D7-471E-41A3-89D4-9FF5B60E7814 Q39239811-A67FE65C-6D4E-4E12-B3C5-283F84F52E8B Q39255870-5531FD4C-F2DC-47DE-9769-7542964BD36F Q41146384-F29B4426-5B2C-4354-A625-2910DEDDEB2E Q49719211-02CF262B-5EEE-493D-B67A-EB289A024851 Q50069952-04AD987A-E56B-49D7-A3D1-471CB4C4F079 Q51363424-0B3A3769-45BC-4C47-81C6-316039946A38 Q55026099-9511CF5B-85E9-4ED8-A1B1-1F91EA7E3B55

P2860

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

http://www.wikidata.org/entity/Q35096719

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

@ast

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

@en

type

label

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

@ast

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

@en

prefLabel

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

@ast

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

@en

P1433

Q35096719-728280FF-045C-4695-B0A6-E8715F908518

P1476

Q35096719-F34BBA86-2E7C-4152-969B-BB1C0D8C4935

P2093

Q35096719-3DBE17E9-FAC3-4C9F-9FCF-1F3948065ED3

Q35096719-79C847C4-CA76-4FCE-BAE7-0436A67BE894

Q35096719-7AC5927C-3AC2-426D-8415-3C592F0F125D

Q35096719-8153D294-8AC0-4300-A8D1-EE35F76BE83F

Q35096719-947569A3-8790-437A-95FE-A7EFE1E2A0CE

Q35096719-AE34EFDB-1BD9-4B05-9F71-8CDC5923DBEE

Q35096719-EA285A3E-A6AC-4FCE-B41B-168A4A5CACAC

P2860

Q35096719-02DA815F-D832-499A-92DD-D9B6B079533C

Q35096719-1384DE36-E3E6-46FB-BEAF-E6AC125A479D

Q35096719-1D525C6F-9F5A-4ADD-A613-F69782D29FA1

Q35096719-1E3F06DD-833F-421A-98A0-A03F67E8BED3

Q35096719-1FEAA1B8-D0FC-45FB-9C3C-920FAD1A4D4F

Q35096719-289AD39E-B66A-408D-9B82-21AD3064DA86

Q35096719-28A15967-0EAA-4A71-942C-426E63A169BF

Q35096719-2CF61166-E7CF-407C-AF14-FFFB4A4E1264

Q35096719-2EDA03CC-BD34-435E-B406-860470F223FA

Q35096719-31E789D1-F699-4FF6-B735-4BDA91042CF3

P304

Q35096719-C8072167-8A05-495B-8357-D74296CEC1E4

P31

Q35096719-CDCFF629-A3A1-486D-BE7F-9E7D54A4434E

P356

Q35096719-7CEABA80-83A8-4139-BE18-9CDD983A5E01

P433

Q35096719-35FAE4E1-6B99-447C-B8A0-D8CB412E6EBF

P478

Q35096719-873CD12C-6664-4E71-AFA1-9459C4CF379C

P50

Q35096719-734BF542-DFB0-49F2-B58A-9B592339F5D5

P577

Q35096719-0DE87E39-B971-41A0-8B5B-B372918205E0

P698

Q35096719-819DC336-619B-4EDB-BA27-927108E9FE12

P932

Q35096719-8E784E1F-B809-478C-AB6C-75BBE526417C

P356

P1433

Journal of Bone and Mineral Research

P1476

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

@en

P2093

Christopher L Newman

http://www.w3.org/2001/XMLSchema#string

Ina Kramer

http://www.w3.org/2001/XMLSchema#string

Matthew R Allen

http://www.w3.org/2001/XMLSchema#string

Michaela Kneissel

http://www.w3.org/2001/XMLSchema#string

Neal X Chen

http://www.w3.org/2001/XMLSchema#string

Sharon M Moe

http://www.w3.org/2001/XMLSchema#string

Vincent H Gattone

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of PTH on osteocyte function

Control of bone mass and remodeling by PTH receptor signaling in osteocytes

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment

WNT signaling in bone homeostasis and disease: from human mutations to treatments

Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?

PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop

Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee

The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

P304

499-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.2372

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25407607

http://www.w3.org/2001/XMLSchema#string

P932

4333005

http://www.w3.org/2001/XMLSchema#string